Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

718
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
718
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

588
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
588
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.8K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.8K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.2K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.2K
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

1.7K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Scoping review of community-wide screening to break the chain of TB transmission.

IJTLD open·2026
Same author

A structured approach to promote equity in spatial accessibility to TB services during private sector engagement.

IJTLD open·2026
Same author

Xpert MTB/RIF Ultra 'trace': considerations for diagnostics.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

The risk of rifampicin-resistant TB after drug-susceptible TB treatment.

IJTLD open·2025
Same author

Comparing short-term mortality between people with and without HIV admitted to the intensive care unit: A single-centre matched cohort study (2000-2019).

HIV medicine·2024
Same author

Risk factors for and timing of presumptive recurrent TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same journal

Rifamycin-based regimens for preventive treatment in low TB incidence countries.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

The Kochi Declaration 2024 - A catalyst for global TB elimination through private sector engagement.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Preventing lung function decline and pleural thickening after pleural TB: a systematic review.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Aircraft contact investigations for TB on domestic and inbound flights to the United States.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Treatment outcome of extracorporeal membrane oxygenation in critically ill patients with pulmonary TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Factors associated with sputum culture positivity of <i>Mycobacterium tuberculosis</i>.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
See all related articles

Related Experiment Video

Updated: Mar 7, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K

Isoniazid-resistant tuberculosis: a cause for concern?

H R Stagg1, M C Lipman2, T D McHugh3

  • 1Institute of Global Health, UCL, London, UK.

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
|February 25, 2017
PubMed
Summary
This summary is machine-generated.

Isoniazid (INH) resistance is a significant global challenge in tuberculosis (TB) control. Re-evaluating the impact of non-multidrug-resistant INH resistance is crucial for effective TB treatment strategies.

More Related Videos

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

82.1K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K

Related Experiment Videos

Last Updated: Mar 7, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.2K
Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

82.1K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K

Area of Science:

  • Microbiology
  • Epidemiology
  • Pharmacology

Background:

  • Isoniazid (INH) is a cornerstone drug for global tuberculosis (TB) treatment.
  • Significant rates of non-multidrug-resistant (MDR) INH resistance exist, particularly in former Soviet Union countries (16.1%) and elsewhere (7.5%).
  • INH resistance is associated with adverse treatment outcomes, including relapse and mortality.

Purpose of the Study:

  • To highlight the complex relationship between genetic mutations and INH resistance phenotypes.
  • To underscore the limitations of current rapid sequencing techniques for guiding treatment.
  • To re-evaluate the global importance and clinical consequences of non-MDR INH resistance.

Main Methods:

  • Review of existing epidemiological data on INH resistance.
  • Analysis of the clinical impact of INH resistance.
  • Assessment of the genetic underpinnings of INH resistance.

Main Results:

  • The genotype-phenotype relationship for INH resistance is complex, limiting diagnostic utility of rapid sequencing.
  • INH resistance impacts treatment effectiveness and preventive therapy.
  • Knowledge gaps exist regarding the epidemiology, clinical consequences, and role of INH resistance in the MDR-TB epidemic.

Conclusions:

  • Non-MDR INH resistance requires urgent re-evaluation by global and national TB control programs.
  • Understanding INH resistance is critical for optimizing TB treatment regimens and preventing MDR-TB spread.
  • Further research is needed to address knowledge gaps in INH resistance epidemiology and clinical impact.